




## PFS

Study or Subgroup	log(Hazard Ratio)	SE	Favours PARP inhibitor		Favours Chemotherapy		Hazard Ratio		Year
			Total	Weight	Total	Weight	IV, Random, 95% CI		
OlympiAD NEJM 2017	-0.54472718	0.158374	205	43.9%	97	52.6%	0.58 [0.43, 0.79]	2017	
EMBRACA NEJM 2018	-0.61618614	0.140079	287	56.1%	144	56.1%	0.54 [0.41, 0.71]	2018	
<b>Total (95% CI)</b>			<b>492</b>	<b>100.0%</b>	<b>241</b>	<b>100.0%</b>	<b>0.56 [0.45, 0.68]</b>		


Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.11, df = 1 (P = 0.74); I<sup>2</sup> = 0%  
Test for overall effect: Z = 5.57 (P < 0.00001)



## OS

Study or Subgroup	log(Hazard Ratio)	SE	Favours PARP inhibitor		Favours Chemotherapy		Hazard Ratio		Year
			Total	Weight	Total	Weight	IV, Random, 95% CI		
OlympiAD Ann Oncol 2019	-0.10536052	0.158809	205	45.1%	205	45.1%	0.90 [0.66, 1.23]	2019	
EMBRACA NEJM 2018	-0.27443685	0.167374	287	47.4%	144	47.4%	0.76 [0.55, 1.06]	2018	
<b>Total (95% CI)</b>			<b>492</b>	<b>100.0%</b>	<b>241</b>	<b>100.0%</b>	<b>0.83 [0.66, 1.04]</b>		


Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.54, df = 1 (P = 0.46); I<sup>2</sup> = 0%  
Test for overall effect: Z = 1.61 (P = 0.11)



## 治療中止


Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Ratio		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	10	205	7	91	62.1%	0.63	[0.25, 1.61]	2019
EMBRACA	17	286	11	126	62.1%	0.68	[0.33, 1.41]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>0.66</b>	<b>[0.37, 1.18]</b>	

Total events: 27 (PARP inhibitor), 18 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.01, df = 1 (P = 0.91); I<sup>2</sup> = 0%  
Test for overall effect: Z = 1.40 (P = 0.16)



Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Difference		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	10	205	7	91	45.1%	-0.03	[-0.09, 0.03]	2019
EMBRACA	17	286	11	126	54.9%	-0.03	[-0.08, 0.03]	2018
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>-0.03</b>	<b>[-0.07, 0.01]</b>	


Total events: 27 (PARP inhibitor), 18 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.00, df = 1 (P = 0.99); I<sup>2</sup> = 0%  
Test for overall effect: Z = 1.31 (P = 0.19)



## 貧血 (Grade3以上)


Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Ratio		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	33	205	4	91	31.7%	3.66	[1.34, 10.03]	2019
EMBRACA	111	286	8	126	68.3%	6.11	[3.08, 12.14]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>5.20</b>	<b>[2.95, 9.16]</b>	

Total events: 144 (PARP inhibitor), 12 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.68, df = 1 (P = 0.41); I<sup>2</sup> = 0%  
Test for overall effect: Z = 5.69 (P < 0.00001)



Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Difference		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	33	205	4	91	50.2%	0.12	[0.05, 0.18]	2019
EMBRACA	111	286	8	126	49.8%	0.32	[0.25, 0.40]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>0.22</b>	<b>[0.02, 0.42]</b>	


Total events: 144 (PARP inhibitor), 12 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 17.79, df = 1 (P < 0.0001); I<sup>2</sup> = 94%  
Test for overall effect: Z = 2.12 (P = 0.03)



## 好中球数減少 (Grade3以上)


Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Ratio		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	19	205	24	91	37.0%	0.35	[0.20, 0.61]	2019
EMBRACA	60	286	48	126	63.0%	0.55	[0.40, 0.76]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>0.47</b>	<b>[0.30, 0.71]</b>	

Total events: 79 (PARP inhibitor), 72 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.05; Chi<sup>2</sup> = 1.93, df = 1 (P = 0.16); I<sup>2</sup> = 48%  
Test for overall effect: Z = 3.52 (P = 0.0004)



Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Difference		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	19	205	24	91	49.1%	-0.17	[-0.27, -0.07]	2019
EMBRACA	60	286	48	126	50.9%	-0.17	[-0.27, -0.07]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>-0.17</b>	<b>[-0.24, -0.10]</b>	


Total events: 79 (PARP inhibitor), 72 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.00, df = 1 (P = 1.00); I<sup>2</sup> = 0%  
Test for overall effect: Z = 4.84 (P < 0.00001)



## 嘔吐 (全Grade)

Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Ratio		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	66	205	14	91	46.2%	2.09	[1.24, 3.52]	2019
EMBRACA	71	286	29	126	53.8%	1.08	[0.74, 1.57]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>1.46</b>	<b>[0.77, 2.80]</b>	

Total events: 137 (PARP inhibitor), 43 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.17; Chi<sup>2</sup> = 4.07, df = 1 (P = 0.04); I<sup>2</sup> = 75%  
Test for overall effect: Z = 1.16 (P = 0.25)



Study or Subgroup	PARP inhibitor		Chemotherapy		Weight	Risk Difference		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
OlympiAD	66	205	14	91	49.0%	0.17	[0.07, 0.27]	2019
EMBRACA	71	286	29	126	51.0%	0.02	[-0.07, 0.11]	2019
<b>Total (95% CI)</b>		<b>491</b>		<b>217</b>	<b>100.0%</b>	<b>0.09</b>	<b>[-0.06, 0.24]</b>	

Total events: 137 (PARP inhibitor), 43 (Chemotherapy)  
Heterogeneity: Tau<sup>2</sup> = 0.01; Chi<sup>2</sup> = 4.94, df = 1 (P = 0.03); I<sup>2</sup> = 80%  
Test for overall effect: Z = 1.22 (P = 0.22)

